I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Diabetic Retinopathy

What's new

Sign up or login to unlock the full suite of MEDICALLY features

Feb 16 / Roche and Genentech
Implementation of Optimized Surgical Steps for the PDS and the Incidence of Endophthalmitis and Associated Patient Outcomes
This presentation decribes results from a retrospective analysis which examined the impact of surgical improvements on endophthalmitis incidence and patient outcomes over time in patients receiving the Port Delivery Platform with ranibizumab (PDS) in the PDS clinical development program from 2016 to 2024. A trend for improvement in endophthalmitis incidence and patient outcomes was observed after June 2020. Key updates, increased awareness, better monitoring and management in the PDS clinical trial program have all contributed to this positive trend.

Sign up or login to unlock the full suite of MEDICALLY features

Oct 18 / Roche and Genentech
Comparison of Diabetic Retinopathy Progression With 7 Field and Ultrawide Imaging in the Phase 3 YOSEMITE/RHINE Studies
This presentation describes the results of a treatment-agnostic analysis comparing diabetic retinopathy (DR) severity assessment on gold-standard 7F vs ultrawide field (UWF) color fundus photographs from patients enrolled in the YOSEMITE and RHINE trials for DME.

Sign up or login to unlock the full suite of MEDICALLY features

Sep 26 / Roche
Watch the recording of the EURETINA symposium "Is Continuous Drug Delivery the Key to Transforming Long-term Outcomes in Retinal Diseases?"
Despite advances in the treatment of retinal diseases with anti-vascular endothelial growth factor therapies, in the real world intravitreal injections remain burdensome and some patients cannot extend their treatment intervals. This symposium explores the latest innovations in continuous drug delivery for the treatment of chronic retinal diseases. It provides an update on the return of the Port Delivery System with ranibizumab (PDS), including ongoing efforts with the Port Delivery Platform, and reviews the latest PDS clinical data for long-term maintenance of vision and retinal anatomy in patients with neovascular age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Experts also discuss their experience with the PDS in the clinic and the real world.

Sign up or login to unlock the full suite of MEDICALLY features

Sep 23 / Roche
View the EURETINA symposium "Is Continuous Drug Delivery the Key to Transforming Long-term Outcomes in Retinal Diseases?"
Despite advances in the treatment of retinal diseases with anti-vascular endothelial growth factor therapies, in the real world intravitreal injections remain burdensome and some patients cannot extend their treatment intervals. This symposium explores the latest innovations in continuous drug delivery for the treatment of chronic retinal diseases. It provides an update on the return of the Port Delivery System with ranibizumab (PDS), including ongoing efforts with the Port Delivery Platform, and reviews the latest PDS clinical data for long-term maintenance of vision and retinal anatomy in patients with neovascular age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Experts also discuss their experience with the PDS in the clinic and the real world.

Sign up or login to unlock the full suite of MEDICALLY features

Sep 15 / Roche and Genentech
Port Delivery System With Ranibizumab for Continuous Treatment in Diabetic Retinopathy: First Readout of 2-Year Data From the Phase 3 Pavilion Trial
Efficacy and safety results from Pavilion year 2 are presented, demonstrating maintenance of DRSS improvement over 2 years, along with safety data consistent with primary analyses.

Sign up or login to unlock the full suite of MEDICALLY features

Jul 18 / Roche and Genentech
Port Delivery System With Ranibizumab for Continuous Treatment in Diabetic Retinopathy: First Readout of 2-Year Data From the Phase 3 Pavilion Trial
Efficacy and safety results from Pagoda and Pavilion year 2 are presented for the first time, demonstrating maintenance of vision and anatomic gains, and continued disease control, respectively, over 2 years, along with safety data consistent with primary analyses.

Ask a question or share feedback